Objective: To compare the hematological effects of carboplatin plus cyclophosphamide, and carboplatin plus
paclitaxel chemotherapy for first line treatment of epithelial ovarian cancer (EOC).
Material and Method: A retrospective study was conducted between January 2003 and May 2006 on 29
patients who received 145 cycles of carboplatin, area under the curve (AUC) 6 plus cyclophosphamide 600
mg/mm2 (CC) intravenous and on 11 patients who received 65 cycles of carboplatin AUC 5 plus paclitaxel 175
mg/mm2 (CP) intravenous chemotherapy for the first line treatment of epithelial ovarian cancer. They had no
history of hematologic disease and complete blood count (CBC), renal function and liver function tests were
normal.
Results: Both groups were similar regarding age, body mass index, performance status and stage of cancer.
Hematological effects were found in 61 of 145 cycles (42.1%) in CC group and 33 of 65 cycles (50.8%) in CP
group (p = 0.05). Twenty patients received all 6 cycles of chemotherapy in the CC group and 10 patients in the
CP group. Fifteen of 20 patients (75%) and 8 of 10 patients (80%) had hematologic effect of at least one cycle
found in the CC and the CP groups, respectively (p = 0.05). There were no treatment-related deaths in both
arms.
Conclusion: Hematological effects did not differ in carboplatin AUC 6 plus cyclophosphamide 600 mg/mm2
regimen and carboplatin AUC 5 plus paclitaxel 175 mg/mm2 regimen and both regimens were accepted
adverse effect in the first line treatment of EOC.

Keywords: Hematological effect, Carboplatin, Cyclophosphamide, Paclitaxel